GSK, Verily launch $715 million bet on bioelectronic medicines

The newly created company aims to develop tiny, implantable devices to treat chronic diseases by modifying electrical signals in the body.

By Ned Pagliarulo • Aug. 1, 2016

Bayer leans on partnering for new growth

BioPharma Dive spoke with Bayer’s Head of Innovation about why partnerships are vital for staying competitive and expanding into new areas. 

By Nicole Gray • July 31, 2016

Editas teams up with Italian gene therapy institute

The two aim to develop stem cell-based and T-cell therapies for rare diseases through a three-year collaboration. 

By Nicole Gray • July 29, 2016

US, UK pledge to combat antibiotic resistance through new alliance

Called Carb-X, the partnership brings together governmental, academic and industry-based experts to address "super bacteria" before resistance becomes unmanageable.

By Nicole Gray • July 29, 2016

Pfizer may sell its stake in Latin America's largest manufacturer

A Reuters report suggests Teva and Mylan are some of the companies interested in buying Pfizer's 40% stake in a Brazilian joint venture.

By Nicole Gray • July 28, 2016

GSK enters $230 million licensing deal with Janssen

GlaxoSmithKline saw an opportunity to develop a new asthma treatment using the IL-33 pathway.

By Nicole Gray • July 28, 2016

US regulators clear Teva, Allergan generics deal

But the Israeli drugmaker will have to sell off nearly 80 drugs in order to clear antitrust concerns raised by the Federal Trade Commission. 

By Ned Pagliarulo • July 27, 2016

Janssen: Bristol-Myers' newest Opdivo combo research partner

A number of companies have recently looked to team up with Bristol-Myers as its checkpoint inhibitor Opdivo continues to rack up approvals. 

By Nicole Gray • July 27, 2016

Kite eyes off-the-shelf T-cell therapies with UCLA research deal

A leader in the race to develop an autologous CAR-T therapy, Kite appears to be hedging its bets with the new agreement. 

By Nicole Gray • July 26, 2016

Swiss group Galencia buys US biotech Relypsa for $1.5 billion

Relypsa's recently approved kidney drug became morere valuable after AstraZeneca saw its competing treatment snubbed by the FDA. 

By Ned Pagliarulo • July 21, 2016

Mylan gets 'all clear' from EU regulators for $7.2 billion Meda deal

Together, the two generics companies would have a foothold in many emerging markets.

By Nicole Gray • July 21, 2016

Celgene bolsters cancer pipeline with another big biotech deal

Cambridge biotech Jounce Therapeutics will receive $225 million upfront plus a hefty $2.3 billion in potential milestone payments tied to its immuno-oncology candidates. 

By Edwin Lopez • July 19, 2016

Teva raises $15 billion through bond sale

Proceeds from the sale will help fund Teva's $40.5 billion acquisition of Allergan's generics division. 

By Nicole Gray • July 19, 2016

High-profile VC firm hires former Merck exec as chief medical officer

Flagship Ventures has been active in supporting biotech firms coming out of Cambridge, MA. 

By Nicole Gray • July 14, 2016

Teva, Allergan generics deal to close 'at any time now'

Underscoring Teva's confidence in winning final U.S. approval for the deal, the Israeli drugmaker also put out rosy revenue projections through 2019. 

By Edwin Lopez • July 13, 2016

Nichi-Iko expands into US with $736 million Sagent buy

Currently dependent on the Japanese market, Nichi-Iko has designs to become a generics player internationally. 

By Nicole Gray • July 12, 2016

Medicines Patent Pool expands access to HIV, hepatitis C drugs with new deals

Four of the licensing agreements with the UN-backed health group covered Bristol-Myers Squibb's Daklinza.

By Nicole Gray • July 11, 2016

Moderna and Vertex partner to target cystic fibrosis with RNA therapies

Vertex will pay $40 million upfront to Moderna, with the potential for another $275 million in milestone payments. 

By Nicole Gray • July 7, 2016

Valeant mulling sale of dermatology assets to Spanish Almirall: report

Although Valeant has made some steps toward recovering from a disastrous first quarter, the company still faces a substantial debt load. 

By Nicole Gray • July 6, 2016

Despite sluggish IPO market, biotechs continue to lead the way

Nine out of 12 venture-backed IPOs in the second quarter were for biotech firms, according to a new report. 

By Nicole Gray • July 6, 2016

Sanofi, Army partner to hasten Zika vaccine trials

The Walter Reed Army Institute of Research will transfer its technology to Sanofi for Phase 2 testing and regulatory strategy. 

By Edwin Lopez • July 6, 2016

Medivation enters takeover talks with Sanofi after rejecting new bid

But Sanofi will have company: Medivation said it had also agreed to open its books to a number of other interested parties. 

By Ned Pagliarulo • July 5, 2016

Chinese biotech CStone raises $150 million in new financing

A former Sanofi exec will head up the new company, which aims to become a research leader in China. 

By Nicole Gray • July 5, 2016

Bristol-Myers buys Cormorant Pharma, eyes cancer combo potential

While Bristol is on the hook for only $95 million in upfront and near-term payments, the deal could be worth over $500 million if all milestones are hit. 

By Ned Pagliarulo • July 5, 2016

Pfizer makes bid for Bind after repayment woes

A demand for accelerated repayment on a $15 million loan led Bind to file for bankruptcy in May. 

By Nicole Gray • July 5, 2016